Other MAO-B targeted PET ligands such as [18F]THK5351 and [11C]deuterium-L-deprenyl have been tested in MS patients and were found to add incremental value by identifying reactive astrocytes in a subset of inactive MS lesions 255, 256. This evidence concerns the gene MAOB and myeloid sarcoma.